Adocia SA · EURONEXT:ADOC

Adocia SA — Investor Presentation (June 2018)

35 slides from Adocia SA's investor presentation, June 2018

  1. Slide 1: Adocia Corporate Presentation June 2018

    Slide 1: Adocia Corporate Presentation June 2018

    ADOCIA INNOVATIVE MEDICINE FOR EVERYONE, EVERYWHERE Corporate Presentation June 2018

  2. Slide 2: Disclaimer

    Slide 2: Disclaimer

    INTRO Disclaimer This corporate presentation (the “Presentation”) has been prepared by ADOCIA (the “Company”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include this document, any oral presentation accompanying t

  3. Slide 3: ADOCIA in summary

    Slide 3: ADOCIA in summary

    ADOCIA ADOCIA in summary Business model delivers cost-effective innovation based on already-approved 1 proteins, enhanced with BioChaperone® Key clinical diabetes assets including ultra-rapid insulin BC Lispro, modern premix 2 BC Combo, ready-to-use BC Glucagon, and BC Pramlintide Insulin 3 $135M li

  4. Slide 4: Adocia's management and team

    Slide 4: Adocia's management and team

    ADOCIA Adocia’s management and team Gérard Soula Olivier Soula Valérie Rémi Soula Steve Daly PhD, MBA PhD, MBA Danaguezian PhD, MBA President & CEO Deputy General Manager, Chief Financial Officer Director of BD & Legal US General Manager Co-founder R&D Director Co-founder Co-founder ▪ Focused on del

  5. Slide 5: BioChaperone Technology

    Slide 5: BioChaperone Technology

    BIOCHAPERONE TECHNOLOGY 5 June 2018

  6. Slide 6: BioChaperone unlocks the potential of proteins and peptides

    Slide 6: BioChaperone unlocks the potential of proteins and peptides

    ADOCIA BioChaperone® unlocks the potential of proteins and peptides and their combinations in a cost-effective way BioChaperone® Proteins and peptides (insulin, GLP-1 RA, pramlintide, (library of molecules) glucagon, teduglutide…) [BioChaperone® Protein] Complex ✓ Improved solubility ✓Improved stabi

  7. Slide 7: BioChaperone-enabled innovation in diabetes and beyond

    Slide 7: BioChaperone-enabled innovation in diabetes and beyond

    ADOCIA BioChaperone-enabled innovation in diabetes and beyond Diabetes clinical pipeline Preclinical pipeline In vitro PC Phase I/II Phase III In vitro PC Phase I/II BC Lispro U100 Diabetes THDB BC Lispro U200 BC Gla GLP-1 THDB BC Combo Other indications (BC Gla Lis) BC GLP-2 Short Bowel Syndrome Hi

  8. Slide 8: Adocia Lead Insulin Programs

    Slide 8: Adocia Lead Insulin Programs

    ADOCIA LEAD INSULIN PROGRAMS BIOCHAPERONE LISPRO & BIOCHAPERONE COMBO 8 June 2018

  9. Slide 9: People with diabetes require simpler, more physiologic treatments

    Slide 9: People with diabetes require simpler, more physiologic treatments

    MARKET People with diabetes require simpler, more physiologic treatments 415M 1 26M2 ▪ Despite 100 years of medical treatment, long-term consequences of diabetes remain a major issue people with on insulin diabetes in 2015 ▪ There is a need to address the underlying complexity of diabetes ▪ With mor

  10. Slide 10: BioChaperone insulins fit the need for innovation in a rapidly evolving insulin market

    Slide 10: BioChaperone insulins fit the need for innovation in a rapidly evolving insulin market

    MARKET BioChaperone Insulins formulations fit the need for innovation in a rapidly evolving insulin market ▪ Diabetes injectable drugs market growth is driven by innovation: ▪ Drugs: ultra-rapid insulin, multi-agent combinations, co-agonists… ▪ Diabetes management: development of integrated solution

  11. Slide 11: Adocia and Tonghua Dongbao entered a strategic alliance

    Slide 11: Adocia and Tonghua Dongbao entered a strategic alliance

    TONGHUA Adocia and Tonghua Dongbao entered a strategic DONGBAO alliance to develop best-in-class insulins ▪ Adocia and Tonghua Dongbao (THDB) strategic alliance: ✓ Licensing agreements for BioChaperone (BC) Lispro & BC Combo ✓ Supply agreements for insulins glargine and insulin lispro ▪ THDB is the

  12. Slide 12: Strategic licensing deals with THDB for BC Lispro & BC Combo

    Slide 12: Strategic licensing deals with THDB for BC Lispro & BC Combo

    LICENSE Strategic licensing deals with THDB for BC Lispro & BC Combo on Chinese market >100M1 ▪ Large and underserved Chinese insulin market features multiple drivers for growth People with ▪ Rapidly growing (CAGR 12%)2, with the number of treated patients set to double in the diabetes in 65%2 next

  13. Slide 13: Strategic supply agreement with THDB opens global opportunities

    Slide 13: Strategic supply agreement with THDB opens global opportunities

    SUPPLY Strategic supply agreement with THDB opens global opportunities for Adocia ▪ With access to stable, high-quality insulin lispro and insulin glargine supplies, Adocia now gains full control over BC Lispro and BC Combo development ▪ Partnering opportunities are multiplied: ✓ Companies focused o

  14. Slide 14: BC Lispro: ultra-rapid insulin with best-in-class potential

    Slide 14: BC Lispro: ultra-rapid insulin with best-in-class potential

    Licensed to THDB in China BC LISPRO Ultra-rapid insulin with potential for best-in-class ▪ BioChaperone® Lispro could be a differentiated competitor to Fiasp® (1st approved ultra-rapid insulin, Novo Nordisk). ▪ Consistently faster-on and faster-off metabolic effect vs. Humalog® & Novolog® in 252 peo

  15. Slide 15: Ultra-rapid insulin is a key element to close the loop

    Slide 15: Ultra-rapid insulin is a key element to close the loop

    BC LISPRO Ultra-rapid insulin with fast-on and fast-off profile is a key element to « close the loop » Adocia intends to initiate Smart CGM its first Phase 3 trial in the Pumps & pens insulin pump setting 15 June 2018

  16. Slide 16: BC Combo: alternative to premix insulin for type 2 diabetes

    Slide 16: BC Combo: alternative to premix insulin for type 2 diabetes

    Licensed BC COMBO A safer and more efficient alternative to premix to THDB in China insulin for the treatment of type 2 diabetes ▪ Premix products are easier to use than basal-bolus regimens but present $5B inferior prandial coverage and a higher risk of hypoglycemia Premix insulin market (2016)1 ▪

  17. Slide 17: Multihormonal Treatments for Diabetes

    Slide 17: Multihormonal Treatments for Diabetes

    MULTIHORMONAL TREATMENTS FOR DIABETES NEXT GENERATION OF CARE FOR BETTER OUTCOMES 17 June 2018

  18. Slide 18: Multi-hormonal approaches to improve diabetes and obesity management

    Slide 18: Multi-hormonal approaches to improve diabetes and obesity management

    RATIONALE Innovative multi-hormonal approaches aim to improve diabetes and obesity management Insulin In combination BC Glargine GLP-1 (T2D) BC Pramlintide rhIns (T1D & T2D) GLP-1 Amylin In combination In a dual-chamber pump BC Glucagon GLP-1 BC Glucagon with Insulin (T1D) (Obesity) Glucagon As a se

  19. Slide 19: Time-sensitive hormonal pattern maintains normo-glycemia

    Slide 19: Time-sensitive hormonal pattern maintains normo-glycemia

    DIABETES In non-diabetic people, a time-sensitive hormonal pattern maintains normo-glycemia Schematic representation of hormonal pattern1 Insulin Without diabetes With Type 1 diabetes (T1D) Level of secretion Amylin (relative scale) Glucagon GLP-1 GLP-1 Glucagon Insulin Amylin 0 1 2 3 4 5 6 0 1 2 3

  20. Slide 20: BC Pramlintide Insulin: next generation prandial treatment in T1D

    Slide 20: BC Pramlintide Insulin: next generation prandial treatment in T1D

    BC PRAM Next generation of prandial treatment to improve long- INSULIN term outcomes in T1D 79%2 Of diabetics live ▪ BioChaperone Pramlintide Insulin exceptionally tight prandial with severe control1,2,3, potentially lowering the risk of long-term severe complications complications ▪ Multiple hormon

  21. Slide 21: Ready-to-use aqueous formulation of human glucagon

    Slide 21: Ready-to-use aqueous formulation of human glucagon

    BC A ready-to-use aqueous formulation of human glucagon GLUCAGON for acute and chronic use ▪ BioChaperone Glucagon is a ready-to-use aqueous formulation of $400M human glucagon supporting: Forecasted ▪ Rescue treatment of severe hypoglycemia in a ready-to-use market in 20251 autoinjector: current gl

  22. Slide 22: Expanding the Portfolio

    Slide 22: Expanding the Portfolio

    EXPANDING THE PORTFOLIO LEVERAGING BIOCHAPERONE TRACK-RECORD AND VERSATILITY TO ADDRESS NEW THERAPEUTIC TARGETS 22 June 2018

  23. Slide 23: BioChaperone improves approved or NCE proteins and peptides

    Slide 23: BioChaperone improves approved or NCE proteins and peptides

    BC BioChaperone can be used to improve both approved PLATFORM or NCE proteins and peptides BioChaperone/Protein complex ▪ Leveraging Adocia core competencies in protein and peptide formulation to fit partner’s needs ▪ More than 20 clinical trials (Phase 1-3) to date on 6 different pharmaceutical pro

  24. Slide 24: Expanding the use of BioChaperone platform

    Slide 24: Expanding the use of BioChaperone platform

    PIPELINE EXPANSION Expanding the use of BioChaperone platform ▪ BioChaperone Glucagon GLP-1 for the treatment of obesity ▪ Obesity prevalence has tripled from 1975 to 2016 globally2, triggering the development of more aggressive treatment regimens: 36.5%1 of US adults are ▪ Based on BC Glucagon, Ado

  25. Slide 25: Key financial elements

    Slide 25: Key financial elements

    ADOCIA Key financial elements Financial summary Shareholders’ equity (May 2018) Analysts ▪ Listed on Euronext Paris (ADOC) Free Float Soula Family 22.1 % ▪ Jefferies (Peter Welford) 59.6% ▪ Kepler Market (Arsène Guekam) ▪ 6.9M shares outstanding ▪ Oddo (Sébastien Malafosse – Pierre Corby) ▪ Louis Ca

  26. Slide 26: Expected News Flow

    Slide 26: Expected News Flow

    ADOCIA Expected News Flow Pipeline Conferences ▪ BC HUMAN GLUCAGON Adocia will present at the American Diabetes Association 78th ▪ Phase 1/2 expected to launch in H2 18 Scientific Sessions in Orlando, Florida, June 22nd-June 26th: ▪ BC PRAMLINTIDE INSULIN ▪ 2 oral presentations ▪ Results of first-in

  27. Slide 27: Thank you for your kind interest

    Slide 27: Thank you for your kind interest

    THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 contact@adocia.com 27 June 2018

  28. Slide 28: Appendix

    Slide 28: Appendix

    APPENDIX 28 June 2018 ADOCIA f-

  29. Slide 29: Adocia is supported by a top-tier Medical Advisory Board

    Slide 29: Adocia is supported by a top-tier Medical Advisory Board

    ADOCIA Adocia is supported by a top-tier Medical Advisory Board ▪ Dr. Jay Skyler, MD, Chairman, University of Miami (US) ▪ Dr. Vanita Aroda, MD, MedStar Health Research Institute (US) ▪ Dr. Bruce Bode, MD, Emory University (US) ▪ Dr. John Buse, MD, PhD, University of North Carolina (US) ▪ Dr. Eda Ce

  30. Slide 30: HinsBet: affordable prandial insulin for price-sensitive populations

    Slide 30: HinsBet: affordable prandial insulin for price-sensitive populations

    HINSBET Affordable prandial insulin for price-sensitive populations $1B Human prandial ▪ HinsBet is a formulation of human insulin designed to act as rapidly as insulin market an insulin analog (2016)1 ▪ Human insulin is the most common prandial insulin choice in low- income countries, but diffuses

  31. Slide 31: Efficient and affordable intensification options over basal insulin for T2D

    Slide 31: Efficient and affordable intensification options over basal insulin for T2D

    BC Efficient and affordable intensification options over GLAR GLP-1 basal insulin for T2D $2.2B1 2023 Forecast ▪ Combinations of basal insulin and GLP-1 are a new class of treatment for T2D Basal-GLP1 ▪ 50% patients are not controlled on basal insulin alone2 market ▪ 2 products recently approved in

  32. Slide 32: BC Lispro results compared to Humalog U100 in T1DM

    Slide 32: BC Lispro results compared to Humalog U100 in T1DM

    BC LISPRO Results summary compared to Humalog U100 in T1DM subjects 294-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions Biochaperone Lispro: Shorter TMAX, Higher CMAX ▪ BioChaperone Lispro in comparison with and Similar Exposure Greater Earlier Exposure: Faster In Humalo

  33. Slide 33: BC Combo results compared to Lispro Mix 75/25 in T1DM

    Slide 33: BC Combo results compared to Lispro Mix 75/25 in T1DM

    BC COMBO Results summary compared to Conventional Lispro Mix 75/25 in T1DM subjects 295-OR in Novel Therapeutics in T1D, June 13, 2016, 76th ADA Scientific Sessions Mean Unadjusted BG Profiles ± SEM Over 6hr After s.c. Cumulative Percentage of Subjects With BG Values < 63 mg/dL ▪ In this solid mixed

  34. Slide 34: BC Combo results compared to Humalog 75/25 in T2DM

    Slide 34: BC Combo results compared to Humalog 75/25 in T2DM

    BC COMBO Results summary compared to Humalog 75/25 in T2DM subjects 942-P in 12-B Clinical Therapeutics/ New Technology-Insulins, June 11, 2016, 76th ADA Scientific Sessions Smoothed GIR Profiles (0-30h) of 0.8 U/kg BioChaperone Combo, 0.8 Smoothed GIR Profiles (0-2h) of 0.8 U/kg BioChaperone ▪ In t

  35. Slide 35: Thank you for your kind interest

    Slide 35: Thank you for your kind interest

    THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 contact@adocia.com 35 June 2018

Source: Internet Archive copy of adocia.com

More decks from Adocia SA

All 49 Adocia SA decks